$BLTE

Belite Bio (BLTE) presented at the Morgan Stanley conference, highlighting its drug tinlarebant for Stargardt disease. The company cited strong Phase III data, a 36% reduction in lesion progression, and a February 12 PDUFA date. Shares rose 2.35% in after-hours trading to $177.88. The company also discussed its commercial strategy and Japan filing.

On September 9, 2026, significant insider trading activity was reported. Alumis Inc. (ALMS) director acquired $10.7M in shares, while NVIDIA (NVDA) director sold $235.6M. Greenwave (GWAV) CEO bought $8M in shares, and BELITE BIO (BLTE) executives sold $31.9M. Workday (WDAY) director sold $17.9M in shares. Dell (DELL) insiders sold $48.1M. Inhibrx (INBX) and Cytosorbents (CTSO) directors also made notable purchases.

Lin Yu-Hsin (Chief Executive Officer) sold 100,435 shares of BELITE BIO, INC (BLTE) at an average of $190.00 ($180.29–$198.09, $19.08M total) across 19 trades over 2026-09-04 to 2026-09-08 under a Rule 10b5-1 trading plan.

Chuang Hao-Yuan (Chief Financial Officer) sold 67,395 shares of BELITE BIO, INC (BLTE) at an average of $189.98 ($180.16–$198.05, $12.80M total) across 19 trades over 2026-09-04 to 2026-09-08 under a Rule 10b5-1 trading plan.

US equities show divergence with semiconductor and biotech stocks rising, while software stocks fall. Belite Bio (BLTE) and Aehr Test Systems (AEHR) lead gains, while Guidewire Software (GWRE) and lululemon (LULU) lead declines. SanDisk (SNDK), Cohu (COHU), and Cerebras Systems (CBRS) also see notable gains. Fair Isaac (FICO), UiPath (PATH), and Asana (ASAN) experience significant drops.

Belite Bio (BLTE) shares rose 9.0% after the FDA granted priority review to its new drug application for tinlarebant, a treatment for Stargardt disease. The company expects a decision by February 12, 2027, and is preparing for commercial launch, targeting 53,000 patients. Phase III data showed a 35.7% reduction in lesion growth versus placebo. The company projects $563.2 million revenue and $318.3 million earnings by 2029, a 24% upside to its current price.

Analysts made several rating changes: Bernstein upgraded Ormat (ORA) to Market Perform, Morgan Stanley upgraded Shell (SHEL) to Overweight with a $101.30 target, Barclays upgraded W.P. Carey (WPC) to Equal Weight, Baird upgraded Sonida Senior Living (SNDA) to Outperform with a $43 target, and Piper Sandler upgraded Simmons First National (SFNC) to Overweight with a $27.50 target. Canaccord downgraded UiPath (PATH) to Hold with a $17 target, Craig-Hallum downgraded Ambarella (AMBA) to Hold with a

Analysts made several calls: Goldman Sachs reiterated Tesla as neutral, citing Cybercab's cost benefits. Bernstein kept Apple as outperform, noting market share gains. Baird upgraded Sonida Senior Living to outperform. Morgan Stanley upgraded Shell to overweight, expecting acceleration. Piper Sandler upgraded Simmons First National to overweight. Goldman upgraded Vodafone to buy. B. Riley initiated Infleqtion as buy. William Blair kept Nvidia as outperform, approving its Hugging Face acquisition

Fed Governor Waller's comments on holding rates steady sparked a market rally, with the Nasdaq up 1.4% and Bitcoin above $80,000. Analysts upgraded Shell (NYSE: SHEL) to Overweight with a $101.30 target, while downgrading Ambarella (NASDAQ: AMBA) to Hold. StoneX initiated PulteGroup (NYSE: PHM) as Buy and Lennar (NYSE: LEN) as Hold. Major indices closed higher, with the Nasdaq at 26,584, Dow at 53,686, S&P 500 at 7,747, and Russell 2000 at 2,966.

H.C. Wainwright raised its price target on Belite Bio, Inc. ADR (NASDAQ:BLTE) to $214 from $200 and kept a Buy rating after the FDA accepted Belite Bio’s NDA for tinlarebant and granted Priority Review. The firm cited Phase 3 DRAGON results showing a 35.7% reduction in retinal lesion growth vs placebo. FDA PDUFA date is Feb. 12, 2027.